CUIDADO FARMACÊUTICO NO TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOIÉTICAS NO CEARÁ
Article Sidebar
Main Article Content
Abstract
Objectives: To report the experience, evolution and consolidation of pharmaceutical services provided to patients undergoing hematopoietic stem cell transplantation (HSCT) at a university hospital complex in Fortaleza (CE), Brazil. Materials and methods: This report was constructed based on the experience lived by pharmacists of the bone marrow transplant service, as well as by resident pharmacists, during the period from January/2016 to December/2017. The services offered were: health education; dispensation; conciliation and therapeutic monitoring of medications; review of pharmacotherapy; pharmacotherapeutic follow-up and health condition management. Results: It was found that 17 patients hospitalized for HSCT were followed up, from admission conciliation to discharge guidance. At the outpatient clinic, 34 patients were followed up, with 301 pharmaceutical consultations being carried out with recommendations, the main ones being: health care (28.3%) and guidance on medication acquisition (25.5%). Conclusion: Despite the limitations found, this work contributed to the development of the discussion regarding specialized care for HSCT patients and to demonstrate the importance of the pharmacist participating in this care with the multidisciplinary team
Article Details
We transfer the copyright pertaining to the manuscript, accepted for publication in this journal, to the exclusive property of Cadernos da Escola de Saúde, and we agree that partial or total reproduction in any means of dissemination, printed or electronic, without the prior and necessary authorization is requested from the Journal's Board of Directors.
References
2. Chao NJ, Chen BJ. Prophylaxis and treatment of acute graft-versus-host disease. Seminars in hematology. 2006;43(1):32-41.
3. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nature Reviews Immunology. 2012; 12(6):443-58.
4. Mohammadpour N, Elyasi S, Vahdati N, Mohammadpour AH, Shamsara J. A review on therapeutic drug monitoring of immunosuppressant drugs. Iranian journal of basic medical sciences. 2011;14(6):485.
5. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone marrow transplantation. 2006;38(3):169-174.
6. Wang HY, Chan AL, Chen MT, Liao CH, Tian YF. Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplantation proceedings. 2008; 40(7):2319-23.
7. Merten JA, Shapiro JF, Gulbis AM, Rao KV, Bubalo J, Lanum S, et al. Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation. 2013;19(4):509-18.
8. Corrêa PM, Zuckermann J, Fischer GB, Castro MS. Immunosuppressive serum levels in allogeneic hematopoietic stem cell transplantation: pharmaceutical care contribution. Pharmacy Practice (Granada). 2016;14(2).
9. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients’ compliance with immunosuppressive medications. Clinical transplantation. 2001;15(5):330-36.
10. Chisholm-Burns MA, Spivey CA, Garrett C, McGinty H, Mulloy L L. Impact of clinical pharmacy services on renal transplant recipients’ adherence and outcomes. Patient preference and adherence. 2008; 2, 287.
11. Conselho Federal de Farmácia. Serviços Farmacêuticos Diretamente Destinados ao Paciente, à Família e à Comunidade: Contextualização e Arcabouço Conceitual. Brasília: Conselho Federal de Farmácia; 2016.
12. Oliboni L, Camargo AL. Validação da prescrição oncológica: o papel do farmacêutico na prevenção de erros de medicação. Clinical & Biomedical Research. 2009; 29(2).
13. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2018. Oslo, Norway 2017.
14. DRUGDEX system. MICROMEDEX healthcare series [proprietary database on the Internet]. Greenwood Village: Thompson MICROMEDEX. Disponível em http://www-micromedexsolutions-com.ez11.periodicos.capes.gov.br/micromedex2/librarian/. Acesso em: 10/01/2018.
15. Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. Journal of Dermatological Treatment. 2012;23(4):290-304.
16. Fonseca RB, Secoli SR. Terapia farmacológica em transplante de medula óssea: contribuição para a prática de enfermagem. Rev Bras Oncol Clín. 2006; 3(8).
17. Lindenmeyer LP, Goulart VP, Hegele V. Reconciliação medicamentosa como estratégia para a segurança do paciente oncológico. Rev. Bras. Farm. Hosp. Serv. Saúde. 2013;4(4):51-5.
18. Wu HT, Graff LR, Yuen CW. Clinical pharmacy in an inpatient leukemia and bone marrow transplant service. American journal of health-system pharmacy. 2005;62(7):744-7.
19. Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: A systematic review. Journal of Clinical Pharmacy and Therapeutics. 2017.
20. Alexander MD, Rao KV, Khan TS, Deal AM, Alexander MD, Rao, KV, et al. ReCAP: pharmacists’ impact in hematopoietic stem-cell transplantation: economic and humanistic outcomes. Journal of oncology practice. 2016;12(2):147-8.